Concurrent chemotherapy as well as first-generation epidermal progress aspect receptor (EGFR)-tyrosine kinase inhibitors (TKIs) without or with the antiangiogenic realtor as first-line remedy inside superior lungs adenocarcinoma sheltering a great EGFR mutation.